RECOMBINANT PROTEIN MARKET ANALYSIS

Protein expression and purification play a central role in biochemistry. Recombinant proteins can be expressed using prokaryotic systems (E. coli and Bacillus subtilis), eukaryotic systems (yeast, insect cells, mammalian cells), or in vitro systems. A number of new strains, vectors, and tags have been developed in recent years to overcome the limitations of recombinant protein system, such as codon distortion, inclusion body formation, toxicity, protein inactivity, mRNA instability, and lack of post-translational modifications.

Global recombinant protein market is estimated to be valued at US$ 2,808.4 million in 2022 and is expected to exhibit a CAGR of 11.5% during the forecast period (2022-2030).

Figure 1. Global Recombinant Protein Market Share (%), by Product Type, 2022

To learn more about this report, request a free sample copy

Global Recombinant Protein Market- Driver

Recombinant proteins include recombinant hormones, growth factors, interferon, interleukins, blood clotting factors, tumor necrosis factors, thrombolytic drugs, and enzymes for treating major diseases such as diabetes, dwarfism, congestive heart failure, myocardial infarction, cerebral apoplexy, neutropenia, multiple sclerosis, thrombocytopenia, hepatitis, anemia, Crohn’s disease, rheumatoid arthritis, asthma, cancer, among others, which is expected to drive the market growth over the forecast period. Thus, the increasing prevalence of such diseases is expected to drive the market growth. For instance, according to the data provided by the Breastcancer.org, in March 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 51,400 new cases of non-invasive (in situ) breast cancer in 2022.

Figure 2. Global Recombinant Protein Market Share (%), by Region, 2022

To learn more about this report, request a free sample copy

Increasing research and development activities for the development of recombinant protein-based products such as vaccines and other products by the key players in the market is expected to drive the market growth over the forecast period. For instance, in February 2022, CORBEVAX, an indigenously developed receptor binding domain (RBD) recombinant protein sub-unit vaccine for COVID-19, developed by Biological E Limited, a biotechnology and biopharmaceutical company, received approval for Emergency Use Authorization from the Drug Controller General of India (DCGI) for 12-18 years age group. The Department of Biotechnology (DBT) and its Public Sector Undertaking (PSU), Biotechnology Industry Research Assistance Council (BIRAC), had supported the company’s COVID-19 vaccine candidate from pre-clinical stage through Phase III clinical studies.

Global Recombinant Protein Market– Impact of Coronavirus (COVID-19) Pandemic

Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to World Health Organization (WHO) as of October 10, 2022, 44,614,437 people are affected worldwide.

 According to data published by the Organization for Economic Co-operation and Development (OECD) in November 2020, COVID-19 has posed major challenges to the healthcare infrastructure in the Middle East & North Africa region. Some countries such as Lebanon, Morocco, and Tunisia, have been severely impacted with regards to the overall management of the COVID-19 crisis. Moreover, OECD states that countries such as Iran, Syria, Iraq, the Palestinian Authority, Yemen, and Libya faced the lack of hospital beds and low COVID-19 testing capacities.

According to an article published by the Best Practice & Research: Clinical Anesthesiology Journal in November 2020, healthcare facilities all around the world were severely affected due to COVID-19 pandemic. Medical items such as personal protective equipment (PPE) for healthcare workers, sanitizing supplies, toilet paper, hospital equipment, and water were in short supply. Furthermore, the same source stated that the Indian economy, especially the healthcare manufacturing and service sector was negatively impacted due to nationwide lockdowns during COVID-19 pandemic.

Global Recombinant Protein Market: Key Developments

In February 2022, Rockland Immuno chemicals, Inc. (Rockland), a company specialized in life science tools and services, announced that it had completed the acquisition of antibodies-online, a vendor-independent marketplace for antibodies, ELISA kits, and related research reagent. The recombinant protein were used in various kits and reagent thus the acquisition helps to expand recombinant product portfolio.

In June 2021, the Indian government made an investment of Rs. 1,500 crore (US$ 183.9 million) in recombinant protein COVID-19 vaccine, Corbevax, for mass immunization.

Global Recombinant Protein Market: Restraint

The major factors that can hamper growth of the global recombinant protein market over the forecast period include the high cost of recombinant protein products, high cost involved in its manufacturing and complex process of manufacturing. For instance, according to an article published by MDPI, a publisher of open access scientific journals, in July 2019, the costs of a single clinical trial can vary from US$ 5 million for small, non-controlled orphan drug trials to US$ 350 million for large controlled studies. The median estimate is US$ 19 million.

 Global Recombinant Protein Market: Key Players

Major players operating in the global recombinant protein market include Merck KGaA, OriGene Technologies, Inc., Thermo Fisher Scientific Inc., Feldan Therapeutics, ACROBiosystems, Abcam plc., Randox Laboratories Ltd., SOL GROUP, Proteintech Group, Inc, Planet Biotechnology, Inc., INFINITE ENZYMES, INC., ORF Genetics, GenScript, BTL Biotechno Labs Pvt Ltd., Prospec-Tany Technogene Ltd., BPS Bioscience, Inc., Sino Biological, Cape Bio Pharms, Abnova Corporation, GeNext Genomics.